Posted by Michael Wonder on 06 Apr 2026
Padcev, Tavneos clear key step toward reimbursement in Korea
3 April 2026 - Astellas Pharma Korea’s Padcev (enfortumab vedotin) for urothelial carcinoma and Meditip’s Tavneos (avacopan) for rare vasculitides have passed a key reimbursement review step in Korea.
HIRA said Thursday that both drugs were deemed appropriate for reimbursement at its fourth Pharmaceutical Reimbursement Evaluation Committee meeting.
